Indeed, we show that the use of the GSI dibenzazepine (DBZ) in a syngeneic melanoma model results in the reduction of both pro-tumorigenic (Tregs, MDSCs) and anti-tumorigenic cells (CD4+ and CD8+ T cells), essentially leading to overall immunosuppression; and requires staggered delivery of the drug, with a three-day treatment followed by a four-day holiday period to allow the animals to regain weight, as previously demonstrated [16], which may negatively affect the GSI anti-tumor properties. The gene discussed is CD4; the disease is melanoma.